National Research Council Canada

nrc-cnrc.gc.ca

The National Research Council of Canada (NRC) is the Government of Canada's largest research and technology organization. Working with our partners, we're delivering a national platform for innovation. We conduct research, support small and medium-sized companies to help them scale up and compete and we connect Canadian innovators to leading R&D capabilities. We also enable cross-sector partnership and collaboration here at home.

Related News

Cell and Gene Therapy

BIOCYTOGEN COMPLETES A NEW ROUND OF FINANCING TOTALING TENS OF MILLIONS OF DOLLARS

Biocytogen | June 23, 2021

news image

Biocytogen, a worldwide biotechnology organization zeroed in on neutralizer drug innovative work (R&D) utilizing creative genetically designed creature models, today declared the fruitful culmination of another round of financing adding up to a huge number of dollars. The financing was together finished by Lake Bleu Capital, CPE, Octagon Capital and OrbiMed. Biocytogen Pharmaceuticals (Beijing) Co., Ltd. was set up in 2009. Utilizing its primary quality altering innovation, th...

Read More

Industrial Impact, Medical

WILLOW FURTHER OPTIMIZES ITS BUSINESS TO FOCUS ON NEAR-TERM REVENUE GENERATION AND REDUCE CASH BURN

Willow Biosciences Inc. | December 08, 2022

news image

Willow Biosciences Inc. a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients announced today that it has taken additional steps to focus on near-term revenue generation, protect its balance sheet and reduce its cash burn. Since the early part of the year, the Company has reviewed its market opportunities and its portfolio, using a rigorous evaluation process that has taken into consideration ...

Read More

Industrial Impact

PSYCHECEUTICAL COMPLETES ACQUISITION BY BLUE WATER VENTURES INTERNATIONAL

Blue Water Ventures International | January 20, 2022

news image

Psycheceutical, Inc. a biotechnology company dedicated to the development and commercialization of psychedelic medicines, announced the company has been fully acquired by Blue Water Ventures International, Inc. “We are thrilled that this deal has closed and that Psycheceutical is now a wholly-owned subsidiary of a publicly-listed company and has secured important near-term capital to pursue our growth plans. We will immediately begin the next steps of o...

Read More

Industrial Impact

OMASS THERAPEUTICS TO PRESENT AT UPCOMING CONFERENCESOMASS THERAPEUTICS TO PRESENT AT UPCOMING CONFERENCES

OMass Therapeutics | February 21, 2022

news image

OMass Therapeutics a biotechnology company identifying medicines against highly validated target ecosystems, is pleased to confirm that it will be presenting at a number of upcoming banking, business and scientific conferences, as detailed below. “As we develop our unique drug discovery platform, OdyssION™, and progress our pipeline of small molecule therapeutics in rare diseases and immunological conditions, targeting solute carriers, complex-bou...

Read More
news image

Cell and Gene Therapy

BIOCYTOGEN COMPLETES A NEW ROUND OF FINANCING TOTALING TENS OF MILLIONS OF DOLLARS

Biocytogen | June 23, 2021

Biocytogen, a worldwide biotechnology organization zeroed in on neutralizer drug innovative work (R&D) utilizing creative genetically designed creature models, today declared the fruitful culmination of another round of financing adding up to a huge number of dollars. The financing was together finished by Lake Bleu Capital, CPE, Octagon Capital and OrbiMed. Biocytogen Pharmaceuticals (Beijing) Co., Ltd. was set up in 2009. Utilizing its primary quality altering innovation, th...

Read More
news image

Industrial Impact, Medical

WILLOW FURTHER OPTIMIZES ITS BUSINESS TO FOCUS ON NEAR-TERM REVENUE GENERATION AND REDUCE CASH BURN

Willow Biosciences Inc. | December 08, 2022

Willow Biosciences Inc. a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients announced today that it has taken additional steps to focus on near-term revenue generation, protect its balance sheet and reduce its cash burn. Since the early part of the year, the Company has reviewed its market opportunities and its portfolio, using a rigorous evaluation process that has taken into consideration ...

Read More
news image

Industrial Impact

PSYCHECEUTICAL COMPLETES ACQUISITION BY BLUE WATER VENTURES INTERNATIONAL

Blue Water Ventures International | January 20, 2022

Psycheceutical, Inc. a biotechnology company dedicated to the development and commercialization of psychedelic medicines, announced the company has been fully acquired by Blue Water Ventures International, Inc. “We are thrilled that this deal has closed and that Psycheceutical is now a wholly-owned subsidiary of a publicly-listed company and has secured important near-term capital to pursue our growth plans. We will immediately begin the next steps of o...

Read More
news image

Industrial Impact

OMASS THERAPEUTICS TO PRESENT AT UPCOMING CONFERENCESOMASS THERAPEUTICS TO PRESENT AT UPCOMING CONFERENCES

OMass Therapeutics | February 21, 2022

OMass Therapeutics a biotechnology company identifying medicines against highly validated target ecosystems, is pleased to confirm that it will be presenting at a number of upcoming banking, business and scientific conferences, as detailed below. “As we develop our unique drug discovery platform, OdyssION™, and progress our pipeline of small molecule therapeutics in rare diseases and immunological conditions, targeting solute carriers, complex-bou...

Read More